Melanoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 54
• BRAF 18
• PD-L1 21
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• RAS 2
• CTNNB1 0
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• MET 1
• HDAC 1
• IDH 1
• IL-17 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

3 of 3+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F32

  Investigating the mechanisms of KLRG1-mediated immune suppression in regulatory T cells

  Brown University· Providence, United States· US$79,780 awarded in fiscal year 2026· until Oct 2029

• ALLCDC NCCDPHP · R43

  Parents and Schools for Sun Safety (PASS): A Family-Based Skin Cancer Prevention Program for Schools

  Klein Buendel, Inc.· Lakewood, United States· US$311,239 awarded in fiscal year 2026· until Sept 2027

• NIH NCI · R21

  Optimizing TIL Harvest Site and Patient Selection with CD8-PET Imaging

  University of Tx Md Anderson Can Ctr· Houston, United States· US$421,685 awarded in fiscal year 2026· until Aug 2028

• NIH NIAMS · R00

  Investigating the Role of Cancer-Associated Fibroblasts in Immunodetection of Mycosis Fungoides

  Beckman Research Institute/City of Hope· Duarte, United States· US$249,000 awarded in fiscal year 2026· until Aug 2029

• NIH NIA · R43

  RadBot: Next-Generation Drug Discovery for Environmental Stress Resistance Using Longevity Biology

  Ora Biomedical, Inc.· Tukwila, United States· US$299,783 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, France· EU contribution €242,261· until Mar 2029

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Lipopolysaccharide Lipid A Profiling to Guide Microbiome-Supported Immunotherapy in Melanoma (LPS-Pro)

  Universita Degli Studi di Napoli Federico Ii· Napoli, Italy· EU contribution €150,000· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spain· EU contribution €150,000· until Apr 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Decoding Early-Life UVA and Skincare Additive Interactions Driving Melanoma Risk and Progression in Young Adults (PhotoMel)

  Medizinische Universitaet Wien· Wien, Austria· EU contribution €5,709,196· until Aug 2030· 5 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  SPAtial single-CEll omics research training for MELanoma precision medicine (SPACE-MEL)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution €4,565,428· until Aug 2030· 9 countries

10 of 1,011 running projects, newest first. Listed amounts together: US$571.0m + €83.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

  NCT07281924· University of Wisconsin, Madison· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 22
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 47
• Metabolomics 20
• Mass Spectrometry 10
• Flow Cytometry 65
• Immunohistochemistry 107
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 121
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 57
• Machine Learning 49
• Deep Learning 44
• Cohort Studies 78
• Genome-Wide Association Study 22

• A Method for Quantifying Immune Infiltrates and Tertiary Lymphoid Structures in Murine Melanoma Tumors by Multiplex Immunofluorescence.

  Methods Mol Biol, Jan 2027

• Characterization of an Anti-Tryptophan 2,3-Dioxygenase Monoclonal Antibody and Use in a Melanoma Model.

  Methods Mol Biol, Jan 2027

• PRAME predicting outcome in uveal melanoma.

  J Pathol Clin Res, Nov 2026

• Navigating the diagnostic spectrum and challenges of rare sinonasal tumors: Lessons from a tertiary centre.

  Indian J Pathol Microbiol, Oct 2026

• Metabolic Flexibility of Cutaneous Melanoma Cells Upon Autophagy Modulation: An Immunohistochemical Study.

  Microsc Microanal, Oct 2026

• Histiocytoid melanoma presenting as lymphadenopathy and mimicking Rosai-Dorfman disease.

  J Hematop, Oct 2026

• Establishment of Uveal Melanoma Patient-Derived Organoids Using an Air-Liquid Interface System for Translational Research.

  Invest Ophthalmol Vis Sci, Oct 2026

• [Spitz tumors].

  Pathologie (Heidelb), Sept 2026

• Immunohistochemical Predictors in Head and Neck Mucosal Melanoma.

  Head Neck Pathol, Sept 2026

• Schwann Cell Expression Pattern in Human Melanomas: In Silico and Immunohistochemical Analyses.

  Int J Mol Sci, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.